MedTrace Logo

Repeated Injection of GnRH Agonist to Reduce Ovarian Hyperstimulation Syndrome

NCT02022241 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2013-12-27

No results posted yet for this study

Summary

Gonadotropin releasing hormone (GnRH) agonist is sufficient for triggering final oocyte maturation in GnRH antagonist protocol and can significantly reduce incidence of ovarian hyperstimulation syndrome (OHSS) in high-risk patients.

However, lower oocyte yield was reported in patients with lower luteinizing hormone (LH) level post trigger with single injection of GnRH agonist, which might be related to the shorter duration and lower amount of LH induced by GnRH agonist.

Our aim is to study repeated injection of GnRH agonist for preventing OHSS and maintaining clinical outcome in high risk patients who receive controlled ovarian stimulation in GnRH antagonist protocol.

Conditions

  • Infertility and at High Risk of OHSS

Interventions

DRUG

triptorelin

0.2 mg, ih, at night and 0.2 mg, ih, 12 hours later when at least one of the following criteria was reached: (i) serum E2 ≥3500 pg/ml, (ii) ≥18 follicles measuring ≥11 mm.

Sponsors & Collaborators

  • National Natural Science Foundation of China

    collaborator OTHER_GOV

  • Comprehensive Strategic Cooperation Project of Guangdong Province and Chinese Academy of Science

    collaborator OTHER

  • Guangzhou Science and Technology Program key projects

    collaborator OTHER

  • National Key Basic Research Development Plan of China

    collaborator UNKNOWN

  • Chenshiling

    lead OTHER

Principal Investigators

  • Shi-Ling Chen, M.D., Ph.D. · Nanfang Hospital, Southern Medical University

  • Xin Chen, M.D., Ph.D. · Nanfang Hospital, Southern Medical University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2015-12-31
Completion
2016-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02022241 on ClinicalTrials.gov